Stevens-Johnson syndrome/TEN induced by lamotrigine in a patient with a cerebral cavernous malformation: a case report
https://doi.org/10.4081/dr.2024.10007
Accepted: 5 September 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious cutaneous reactions characterized by epidermal and mucocutaneous detachment, most often drug-induced. SJS and TEN are considered the opposite extremes of the same spectrum of disease, where the percentage of skin involvement is <10% in SJS and >30% in TEN; the in-between range is called a SJS/TEN overlap. We present the case of a 64-year-old patient who was treated with lamotrigine, an anti-epileptic drug, and developed SJS/TEN. After being hospitalized and recovering for three days due to the worsening of the clinical presentation, he was transferred to a burn center. Making an early diagnosis and identifying the indicated drug is extremely important to set the appropriate treatment and reduce mortality. Advanced supportive care is required.
Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010;5:39. DOI: https://doi.org/10.1186/1750-1172-5-39
Tomasini C, Derlino F, Quaglino P, et al. From erythema multiforme to toxic epidermal necrolysis. Same spectrum or different diseases? G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr 2014;149:243–61.
Espinosa-Aguilar E-J, Piña-Ballantyne S-A, Espinosa-Aguilar K-L, et al. Steven-Johnson Syndrome Induced by Lamotrigine and Valproic Acid in a Pediatric Patient: A Case Report. Cureus 2023;15:e41267. DOI: https://doi.org/10.7759/cureus.41267
Wang X, Xiong J, Xu W-H, et al. Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis. Seizure 2015;25:52–61. DOI: https://doi.org/10.1016/j.seizure.2014.12.001
Jacobsen A, Olabi B, Langley A, et al. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev 2022;3:CD013130. DOI: https://doi.org/10.1002/14651858.CD013130.pub2
McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134–43. DOI: https://doi.org/10.1056/NEJMoa1013297
Bui VL, Alvarez-Arango S, Stevenson JM. Pharmacogenetics to prevent hypersensitivity reactions to antiepileptic drugs: is testing performed when indicated? Pharmacogenet Genomics 2024;34:16–9. DOI: https://doi.org/10.1097/FPC.0000000000000510
Mushiroda T, Takahashi Y, Onuma T, et al. Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population. JAMA Neurol 2018;75:842–9. DOI: https://doi.org/10.1001/jamaneurol.2018.0278
Aimo C, Mariotti EB, Corrà A, et al. Stevens-Johnson syndrome induced by Vaxvetria (AZD1222) COVID-19 vaccine. J Eur Acad Dermatol Venereol JEADV 2022;36:e417–9. DOI: https://doi.org/10.1111/jdv.17988
Zou H, Daveluy S. Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol 2023;64:e1–10. DOI: https://doi.org/10.1111/ajd.13958
Curtis KK, Dillan MM, Sharma TR, Piktel J. COVID-19 Infection Increases the Development of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Cohort Analysis. J Am Acad Dermatol 2024;S0190-9622(24)00417-1.
Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006;155:722–8. DOI: https://doi.org/10.1111/j.1365-2133.2006.07398.x
Caproni M, Antiga E, Parodi A, et al. Elevated circulating CD40 ligand in patients with
erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006;154:1006–7. DOI: https://doi.org/10.1111/j.1365-2133.2006.07211.x
Marzano AV, Frezzolini A, Caproni M, et al. Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunopathol Pharmacol 2007;20:557–66. DOI: https://doi.org/10.1177/039463200702000313
Cheng L. Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Front Pharmacol 2021;12:588063. DOI: https://doi.org/10.3389/fphar.2021.588063
Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006;126:272–6. DOI: https://doi.org/10.1038/sj.jid.5700068
Hsieh M-H, Watanabe T, Aihara M. Recent Dermatological Treatments for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Japan. Front Med 2021;8 [ Accessed 19 Feb 2024]. Available from: https://www.frontiersin.org/articles/10.3389/fmed.2021.636924. DOI: https://doi.org/10.3389/fmed.2021.636924
Chang H-C, Wang T-J, Lin M-H, Chen T-J. A Review of the Systemic Treatment of Stevens- Johnson Syndrome and Toxic Epidermal Necrolysis. Biomedicines 2022;10:2105. DOI: https://doi.org/10.3390/biomedicines10092105
Haoxiang X, Xu Y, Baoxi W. Lamotrigine-associated with toxic epidermal necrolysis: a case report and Chinese literature review. Int J Dermatol 2014;53:e231-232. DOI: https://doi.org/10.1111/j.1365-4632.2012.05800.x
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
